Investment Thesis
Actuate Therapeutics is a pre-revenue biotech company with severe operational losses (-$17.8M operating income) and negative free cash flow (-$15.5M), indicating no commercialized products generating revenue. Despite adequate liquidity (2.74x current ratio, $16.9M cash), the company is burning cash rapidly with only ~1 year of runway at current burn rates, creating acute financing risk absent near-term catalysts.
Strengths
- Strong liquidity position with $16.9M in cash and 2.74x current ratio providing near-term operational runway
- Zero debt obligations eliminating refinancing risk and balance sheet leverage concerns
- Lean asset base ($17.7M total assets) with modest liability burden ($6.8M), indicating no legacy encumbrances
Risks
- Pre-revenue stage with zero product commercialization and no revenue generation capability
- Severe cash burn of $15.5M annually with only ~1 year of financial runway remaining before depletion
- Negative profitability metrics across all dimensions (ROE -161.6%, ROA -99.8%, operating margin N/A) with no path to profitability visible
- Dilutive financing requirement imminent given runway constraints, likely destroying shareholder value
Key Metrics to Watch
- Cash burn rate and remaining cash runway duration (critical survival metric)
- Clinical trial progress and regulatory milestones for any lead candidates
- Operating expense trends and evidence of cost efficiency improvements
Financial Metrics
Revenue
N/A
Net Income
-17.7M
EPS (Diluted)
$-0.88
Free Cash Flow
-15.5M
Total Assets
17.7M
Cash
16.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-161.6%
ROA
-99.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.74x
Quick Ratio
2.74x
Debt/Equity
0.00x
Debt/Assets
38.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T11:28:17.471029 |
Data as of: 2025-09-30 |
Powered by Claude AI